Orakl Oncology
AI x biology engine that predicts how cancer patients respond to new drugs to derisk oncology drug development
About Orakl Oncology
Orakl Oncology is a Paris-based TechBio company spun out of the Gustave Roussy cancer institute in 2023. It grows tumour organoids from real patients, screens them against drugs at scale and links the results to genomic, transcriptomic, imaging and clinical data. Its AI models use this dataset to predict patient response and clinical trial outcomes. It offers O-Predict for clinical trial decisions and O-Target for target discovery to biopharma partners.
Founders
Diane-Laure Pagès
COO and co-founder
Fanny Jaulin
CEO and co-founder
Gustave Ronteix
CTO and co-founder
- Biotech & Life Sciences
- Paris, France
- Series A
- 2023
- 40 people
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| Series A | Undisclosed | Norrsken VC, Singular | |
| Seed | €11.0m | Singular | |
| Pre-seed | €3.0m | Speedinvest |
